Real-World Outcomes in Advanced Melanoma Patients Treated with First-Line Nivolumab plus Ipilimumab
AuthID
P-00Z-3QR
P-00Z-3QR
© 2024 CRACS & Inesc TEC - All Rights Reserved Privacy Policy | Terms of Service